iPSC-CAR-NK (SNC Stemcell Engineering Group Co., Ltd.)(iPSC-CAR-NK (SNC Stemcell Engineering Group Co., Ltd.))

概要

基本信息

药物类型

CAR-NK、诱导性多能干细胞

别名-

靶点-

作用机制

自然杀伤细胞替代物

治疗领域

肿瘤消化系统疾病皮肤和肌肉骨骼疾病

在研适应症

HER2阳性乳腺癌肝癌

非在研适应症-

原研机构

华夏源细胞工程集团股份有限公司

在研机构

华夏源细胞工程集团股份有限公司

非在研机构-

最高研发阶段药物发现

首次获批日期-

最高研发阶段(中国)药物发现

特殊审评-

关联

100 项与 iPSC-CAR-NK (SNC Stemcell Engineering Group Co., Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 iPSC-CAR-NK (SNC Stemcell Engineering Group Co., Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 iPSC-CAR-NK (SNC Stemcell Engineering Group Co., Ltd.) 相关的专利（医药）

登录后查看更多信息

1

项与 iPSC-CAR-NK (SNC Stemcell Engineering Group Co., Ltd.) 相关的文献（医药）

2018-08-01·Cell Stem Cell1区 · 医学

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

1区 · 医学

Article

作者: Moriarity, Branden S ; Li, Ye ; Hermanson, David L ; Kaufman, Dan S

Chimeric antigen receptors (CARs) significantly enhance the anti-tumor activity of immune effector cells. Although most studies have evaluated CAR expression in T cells, here we evaluate different CAR constructs that improve natural killer (NK) cell-mediated killing. We identified a CAR containing the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain, and the CD3ζ signaling domain to mediate strong antigen-specific NK cell signaling. NK cells derived from human iPSCs that express this CAR (NK-CAR-iPSC-NK cells) have a typical NK cell phenotype and demonstrate improved anti-tumor activity compared with T-CAR-expressing iPSC-derived NK cells (T-CAR-iPSC-NK cells) and non-CAR-expressing cells. In an ovarian cancer xenograft model, NK-CAR-iPSC-NK cells significantly inhibited tumor growth and prolonged survival compared with PB-NK cells, iPSC-NK cells, or T-CAR-iPSC-NK cells. Additionally, NK-CAR-iPSC-NK cells demonstrate in vivo activity similar to that of T-CAR-expressing T cells, although with less toxicity. These NK-CAR-iPSC-NK cells now provide standardized, targeted "off-the-shelf" lymphocytes for anti-cancer immunotherapy.

100 项与 iPSC-CAR-NK (SNC Stemcell Engineering Group Co., Ltd.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2阳性乳腺癌	药物发现	中国	华夏源细胞工程集团股份有限公司	2022-11-30
肝癌	药物发现	中国	华夏源细胞工程集团股份有限公司	2022-11-30